

TGF Beta Receptor Type 1 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/TC9C2E5D66E9EN.html>

Date: December 2019

Pages: 71

Price: US\$ 3,500.00 (Single User License)

ID: TC9C2E5D66E9EN

Abstracts

TGF Beta Receptor Type 1 - Pipeline Review, H2 2019

SUMMARY

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) pipeline Target constitutes close to 18 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report TGF Beta Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Transforming growth factor beta receptor I is a TGF beta receptor encoded by TGFBR1 gene. It is involved in physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. The molecules developed by companies

in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 9 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Central Nervous System, Immunology, Musculoskeletal Disorders and Toxicology which include indications Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Solid Tumor, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Metastatic Breast Cancer, Pulmonary Fibrosis, Sarcomas, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Androgenic Alopecia, Bladder Cancer, Bone Metastasis, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Degenerative Disc Disease, Fallopian Tube Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Bowel Disease, Keloids, Liver Fibrosis, Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Oral Mucositis, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Radiodermatitis, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar, Systemic Sclerosis (Scleroderma), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Ureter Cancer, Urethral Cancer, Uterine Cancer and Wounds.

Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor

R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30)

The report reviews TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects

The report assesses TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Overview

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development

Allander Biotechnologies LLC

Auxagen Inc

Eli Lilly and Co

FBM Therapeutics LLC

GenFleet Therapeutics

MedPacto Inc

Pfizer Inc

Shanghai Yingli Pharmaceutical Co Ltd

SK Chemicals Co Ltd

Synthis LLC

Taisho Pharmaceutical Holdings Co Ltd

TherapyX Inc

Theravance Biopharma Inc

TiumBio Co Ltd

Yuhan Corp

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC

2.7.11.30) - Drug Profiles

(TPX-6001 + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FBM-5712 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galunisertib monohydrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GFH-018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3200882 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugates to Antagonize TGF-beta for Metastatic Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06952229 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology,
Gastrointestinal and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKI-2162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ALK5 for Idiopathic Pulmonary Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRI-011381 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize TGF-Beta Receptor Type 1 and 2 for Diabetic Foot
Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0427736 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vactosertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-14618 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YL-13027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZL-170 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC

2.7.11.30) - Dormant Products

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC

2.7.11.30) - Product Development Milestones

Featured News & Press Releases

Jul 19, 2019: MedPacto passes tech assessment, seeks KOSDAQ listing this year

May 15, 2019: Eli Lilly presents update on phase Ib study of galunisertib at ASCO 2019

Jan 23, 2019: Study Suggests new strategy to treat advanced Prostate Cancer

Dec 21, 2018: MedPacto announce approval for the Vactosertib + Durvalumab

Combination Trial Application

Aug 31, 2017: Promising One-of-a-kind Clinical Trial Adds Immunotherapy to Colorectal Cancer Treatment Protocol

May 18, 2016: Lilly to present data on TGF β small-molecule kinase inhibitor galunisertib at ASCO

May 14, 2013: Lilly Oncology To Release New Pipeline Data On TGF Beta Inhibitor LY2157299 At ASCO 2013

Apr 10, 2013: Lilly Presents Data On TGF-beta Inhibitor LY2157299 At AACR Annual Meeting

Jul 01, 2009: Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecule Activin-Like Kinase 5 Inhibitor (ALK-5) From Pfizer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Allander Biotechnologies LLC, H2 2019
Pipeline by Auxagen Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by FBM Therapeutics LLC, H2 2019
Pipeline by GenFleet Therapeutics, H2 2019
Pipeline by MedPacto Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H2 2019
Pipeline by SK Chemicals Co Ltd, H2 2019
Pipeline by Synthis LLC, H2 2019
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2019
Pipeline by TherapyX Inc, H2 2019
Pipeline by Theravance Biopharma Inc, H2 2019
Pipeline by TiumBio Co Ltd, H2 2019
Pipeline by Yuhan Corp, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Allander Biotechnologies LLC
Auxagen Inc
Eli Lilly and Co
FBM Therapeutics LLC
GenFleet Therapeutics
MedPacto Inc
Pfizer Inc
Shanghai Yingli Pharmaceutical Co Ltd
SK Chemicals Co Ltd
Synthis LLC
Taisho Pharmaceutical Holdings Co Ltd
TherapyX Inc
Theravance Biopharma Inc
TiumBio Co Ltd
Yuhan Corp

I would like to order

Product name: TGF Beta Receptor Type 1 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/TC9C2E5D66E9EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TC9C2E5D66E9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970